Remove 2023 Remove Biotech Remove Collaboration Remove Contract research organization
article thumbnail

Are You Leveraging the Drug Discovery and Early Development Outsourcing Services Ecosystem to Accelerate Growth?

Frost & Sullivan

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. What is driving transformation in the pharma industry? increase from 2022. However, the pharma/biopharma industry shows overall stagnant R&D activity.

article thumbnail

How does your company’s benchmarking performance stack up against the leading precision health companies in the ecosystem?

Frost & Sullivan

Small- to mid-sized pharma/biotech players in APAC are rivaling Europe in clinical trials through multiple CRO partnerships in the region, tapping into a population-rich landscape. Let us coach you on your transformational journey, while we actively support you in fostering collaborative initiatives within your industry’s ecosystem.